Bezlotoxumab can reduce the risk of Clostridium Difficile recurrence

Abstract

Compared to placebo, Bezlotoxumab reduces 10% the risk of recurrence of Clostridium Difficile (17% vs 27%; 95% CI: -15 to -4) in MODIFY I trial, and very similar results are obtained in MODIFY II trial (-10%; 16% vs 26%; 95% CI: -15 to -4). The addition of actoxumab to bezlotoxumab did not improve efficacy (-11%; 16% vs 28%; 95% CI: -17 to -6).